Two Saccharide Radicals Bonded Through Only Oxygen To 4- And 6- Positions Of The Cyclohexyl Ring Patents (Class 514/40)
-
Patent number: 8820323Abstract: The present invention is antibiotic compositions, ventilator-based systems and methods relating to ventilator-associated pneumonia (VAP) and ventilator-associated tracheal (VAT) bronchitis. Antibiotic combinations of fosfomycin and an aminoglycoside, preferably amikacin, are administered via an inline nebulizer within the airway of the ventilator. Humidified conditions create an improved aerosol mist to treat VAP and VAT.Type: GrantFiled: July 12, 2013Date of Patent: September 2, 2014Assignee: Cardeas Pharma CorporationInventor: Alan Bruce Montgomery
-
Patent number: 8822424Abstract: Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Q3, R8 and R9 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.Type: GrantFiled: January 4, 2013Date of Patent: September 2, 2014Assignee: Achaogen, Inc.Inventors: James Bradley Aggen, Adam Aaron Goldblum, Martin Sheringham Linsell, Paola Dozzo, Heinz Ernst Moser, Darin James Hildebrandt, Micah James Gliedt
-
Publication number: 20140242153Abstract: Disclosed are novel methods for making cochleates and cochleate compositions that include introducing a cargo moiety to a liposome in the presence of a solvent. Also disclosed are cochleates and cochleate compositions that include an aggregation inhibitor, and optionally, a cargo moiety. Additionally, anhydrous cochleates that include a protonized cargo moiety, a divalent metal cation and a negatively charge lipid are disclosed. Methods of using the cochleate compositions of the invention, including methods of administration, are also disclosed.Type: ApplicationFiled: January 30, 2014Publication date: August 28, 2014Applicant: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEYInventors: Raphael J. Mannino, Susan Gould-Fogerite, Sara L. Krause-Elsmore, David Delmarre, Ruying Lu
-
Publication number: 20140228312Abstract: The present invention relates to a composition comprising: an antibiotic selected from the group consisting of an aminoglycoside antibiotic, a beta-lactam antibiotic, an ansamycin antibiotic, a macrolide antibiotic, a sulfonamide antibiotic, a quinolone antibiotic, an oxazolidinone antibiotic, a glycopeptide antibiotic, and a mixture thereof; and a fatty acid represented by formula (I), a stereoisomer, a salt or an ester thereof, wherein R1 is a substituted or unsubstituted aliphatic group.Type: ApplicationFiled: October 1, 2012Publication date: August 14, 2014Inventors: Lianhui Zhang, Yinyue Deng
-
Publication number: 20140220108Abstract: The present invention provides, in part, cochleate compositions and methods for making and using same.Type: ApplicationFiled: May 4, 2012Publication date: August 7, 2014Applicants: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY, COORDINATED PROGRAM DEVELOPMENT, LLCInventors: Ruying Lu, Raphael Mannino
-
Publication number: 20140221922Abstract: Bioactive hydroforming luminal liner compositions are formed of an absorbable crystalline amphiphilic polyether-ester-urethane dissolved in a liquid derivative of a polyether glycol that undergoes transformation into a tissue-adhering, resilient interior cover or liner for the controlled release of its bioactive payload at clinically compromised conduits in humans as in the case of bacteria- and yeast-infected vaginal canals, esophagi, and arteries following angioplasty.Type: ApplicationFiled: April 7, 2014Publication date: August 7, 2014Applicant: POLY-MED, INC.Inventors: Shalaby W. Shalaby, David Ingram, Georgios Hilas, Sheila Nagatomi
-
Publication number: 20140221302Abstract: The present invention is antibiotic compositions, ventilator based systems and methods relating to ventilator-associated pneumonia (VAP) and ventilator associated tracheal (VAT) bronchitis. Antibiotic combinations of fosfomycin and an aminoglycoside, preferably amikacin, are administered via an in-line nebulizer within the airway of the ventilator. Humidified conditions create an improved aerosol mist to treat VAP and VAT.Type: ApplicationFiled: July 12, 2012Publication date: August 7, 2014Applicant: Cardeas Pharma, Inc.Inventor: Alan Bruce Montgomery
-
Publication number: 20140221303Abstract: Non-aqueous hydraulic cement compositions comprise a non-aqueous mixture of a powder composition and a non-aqueous water-miscible liquid. In one embodiment, powder composition is a Brushite or Monetite-forming calcium phosphate powder composition. In another embodiment, the powder composition comprises porous ?-tricalcium phosphate (?-TCP) granules and at least one additional calcium phosphate powder. In another embodiment, the powder composition comprises calcium silicate powder. In a further embodiment, the powder composition comprises calcium aluminate powder. In another embodiment, the powder composition is a cement composition and comprises nanopowders having a grain size of less than 1 micron. Hardened cements are formed from such hydraulic cement compositions, and methods of producing hardened cements, kits, and articles of manufacture employ such hydraulic cement compositions.Type: ApplicationFiled: April 7, 2014Publication date: August 7, 2014Applicant: OssDsign ABInventors: Håkan Engqvist, Jonas Åberg
-
Publication number: 20140212504Abstract: Phospholipid based powders for drug delivery applications are disclosed. The powders comprise a polyvalent cation in an amount effective to increase the gel-to-liquid crystal transition temperature of the particle compared to particles without the polyvalent cation. The powders are hollow and porous and are preferably administered via inhalation.Type: ApplicationFiled: April 2, 2014Publication date: July 31, 2014Inventors: Jeffry G. WEERS, Thomas E. TARARA, Luis A. DELLAMARY, Jean G. RIESS, Ernest G. SCHUTT
-
Publication number: 20140205643Abstract: The invention provides a method for combating biofilm, said method comprising contacting a biofilm with an alginate oligomer. The biofilm may be on an animate or inanimate surface and both medical and non-medical uses and methods are provided. In one aspect the invention provides an alginate oligomer for use in the treatment or prevention of a biofilm infection in a subject. In another aspect the method can be used to combat biofilms, on abiotic surfaces, e.g. for disinfection and cleaning purposes.Type: ApplicationFiled: March 21, 2014Publication date: July 24, 2014Applicant: ALGIPHARMA ASInventors: EDVAR ONSOYEN, ROLF MYRVOLD
-
Publication number: 20140206638Abstract: The present invention is directed to the administration of aminoglycosides. In particular, the present invention is directed to compositions and methods for the pulmonary administration of aminoglycosides. According to a preferred embodiment, compositions and methods are provided for the localized treatment of respiratory infections.Type: ApplicationFiled: April 8, 2014Publication date: July 24, 2014Applicant: NOVARTIS AGInventors: Thomas E. TARARA, Jeffry G. WEERS, Geraldine VENTHOYE
-
Publication number: 20140200189Abstract: Artonin I is reported to treat multi-drug resistant Staphlococcus infections.Type: ApplicationFiled: January 14, 2013Publication date: July 17, 2014Inventors: Muhammad Iqbal Choudhary, Saba Farooq, Atia-tul-Wahab, Christian D.A. Fozing
-
Publication number: 20140187497Abstract: A method of forming an ocular delivery device includes exposing a solid, shaped cellulose polymer to a solution including an active pharmaceutical ingredient (API) and a solvent capable of solubilizing the API, wherein the polymer absorbs at least a portion of the solution, including the API and solvent. The method may further include removing at least a portion of the absorbed solvent from the polymer by allowing the absorbed solvent to evaporate from the polymer or by drying the polymer. A variety of cellulose polymers may be used, including hydroxypropyl cellulose. A variety of APIs may be used, including Cyclosporine, Tobramycin and Vancomycin. Ocular delivery devices prepared by the methods may be used to treat a variety of eye disorders.Type: ApplicationFiled: November 22, 2013Publication date: July 3, 2014Applicants: Louisiana State University Agricultural and Mechanical College, ATON PHARMA, INC.Inventors: Jean Theresa JACOB, Kevin John HALLORAN, Yuri MCKEE
-
Patent number: 8748402Abstract: Provided by the present invention are compositions or formulations suitable for application to a patient's eyes which utilizes a topical ophthalmically-acceptable formulation comprising a therapeutically-effective amount of an ophthalmically-active antimicrobial agent, and an ophthalmically-active anti-inflammatory or steroidal agent in combination with physiologic levels of serum electrolytes in an ophthalmic formulation for the treatment of changes in the normal eye condition. The invention also includes methods of treating patient's having an ophthalmic disease, injury or disorder, utilizing the compositions or formulations. Also provided are kits comprising the compositions or formulations and a means of applying the compositions or formulation to the patient's eyes.Type: GrantFiled: February 9, 2012Date of Patent: June 10, 2014Assignee: Bausch & Lomb Pharma Holdings Corp.Inventors: Mark Abelson, Kirk McMullin, Angel Padilla
-
Publication number: 20140155320Abstract: The present invention provides a method of preventing and/or treating a wound infection by introducing to a wound a clear depot comprising a hydrophilic water-soluble pharmaceutically active agent(s) selected from the group consisting of vancomycin, gentamicin, and a mixture thereof, water, a phospholipid, an oil, a pH adjusting agent, and a viscosity modifying agent, wherein the water present in the viscous depot is no more than about 4 wt %, no more than about 2 wt %, or no more than about 0.5 wt % of water relative to the total weight of the depot.Type: ApplicationFiled: October 18, 2011Publication date: June 5, 2014Applicant: DR. REDDY'S LABORATORIES, INC.Inventors: Hailiang Chen, Andrew Xian Chen, Dushyanth Surakanti, Franklin Omuku
-
Patent number: 8734831Abstract: A method for manufacturing a porous ceramic scaffold having an organic/inorganic hybrid coating layer containing a bioactive factor includes (a) forming a porous ceramic scaffold; (b) mixing a silica xerogel and a physiologically active organic substance in a volumetric ratio ranging from 30:70 to 90:10 and treating by a sol gel method to prepare an organic/inorganic hybrid composite solution; (c) adding a bioactive factor to the organic/inorganic hybrid composite solution and agitating until gelation occurs; and (d) coating the porous ceramic scaffold with the organic/inorganic composite containing the bioactive factor added thereto. In accordance with the method, the porous ceramic scaffold may be uniformly coated with the organic/inorganic hybrid composite while maintaining an open pore structure, and stably discharge the bioactive factor over a long period of time.Type: GrantFiled: April 15, 2011Date of Patent: May 27, 2014Assignee: SNU R&DB FoundationInventors: Hyoun-Ee Kim, Shin-Hee Jun, Eun-Jung Lee
-
Publication number: 20140134253Abstract: The present invention provides an inhaled dry powder formulation containing a combination of fosfomycin salt and tobramycin-leucine compound particles. The use of such formulation for the treatment of patients who have Chronic Obstructive Pulmonary Disease (COPD) and who are experiencing or at risk of experiencing acute exacerbation, as well as patients who have other bacterial infections of the respiratory tract, particularly the lower respiratory tract, and methods for treating the same are also provided.Type: ApplicationFiled: May 6, 2012Publication date: May 15, 2014Applicant: Gilead Sciences, Inc.Inventors: Johnny Lai, Josiah Brown, Kevin W. Stapleton
-
Publication number: 20140120171Abstract: A method of parenterally administering a composition, the method including parenterally administering to a person a composition including krill oil in an oil-in-water emulsion. A parenterally applicable pharmaceutical composition, including an oil-in-water emulsion including a phospholipid obtained from a marine crustacean.Type: ApplicationFiled: June 13, 2012Publication date: May 1, 2014Applicant: STABLE SOLUTIONS LLCInventor: David F. Driscoll
-
Publication number: 20140105995Abstract: The present invention provides for silk fibroin-based compositions comprising one or more antibiotic agents for prevention or treatment of microbial contamination, methods of making antibiotic-containing silk scaffold, methods of stabilizing antibiotics in silk scaffolds, and methods for preventing or treating microbial contamination using the antibiotic-containing compositions. Various methods may be used to embed the antibiotic(s) into the silk fibroin-based compositions. The antibiotic-containing compositions of the invention are particular useful for stabilizing antibiotics, preventing bacterial infections, and for medical implants, tissue engineering, drug delivery systems, or other pharmaceutical or medical applications.Type: ApplicationFiled: October 10, 2013Publication date: April 17, 2014Applicant: TRUSTEES OF TUFTS COLLEGEInventors: David L. Kaplan, Bruce Panilaitis, Eleanor M. Pritchard, Fiorenzo Omenetto
-
Publication number: 20140094424Abstract: Microbicidal compositions that exhibit enhanced microbial efficacy are disclosed, as well as methods of producing and using the microbicidal compositions.Type: ApplicationFiled: May 24, 2012Publication date: April 3, 2014Applicant: SIEMENS HEALTHCARE DIAGNOSTICS INC.Inventors: Laura S. Uretsky, Kevin Horan
-
Patent number: 8679532Abstract: A system for treating or providing prophylaxus against a pulmonary infection is disclosed comprising: a) a pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition, and b) an inhalation delivery device. A method for providing prophylaxis against a pulmonary infection in a patient and a method of reducing the loss of antiinfective encapsulated in a lipid-based composition upon nebulization comprising administering an aerosolized pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition is also disclosed.Type: GrantFiled: October 30, 2012Date of Patent: March 25, 2014Assignee: Insmed IncorporatedInventor: Jeff Weers
-
Publication number: 20140079808Abstract: Disclosure is provided for methods of preventing, removing or inhibiting microbial biofilm formation or microbial infection in a plant or plant part thereof, including applying thereto a treatment effective amount of an active compound as described herein, or an agriculturally acceptable salt thereof. Methods of enhancing a microbicide (e.g., including a copper, antibiotic, bacteriophage, etc.) and/or plant defense activator are also provided, including applying an active compound as described herein. Compositions comprising an active compound as described herein in an agriculturally acceptable carrier are also provided, and in some embodiments the compositions further include a microbicide (e.g., including copper, antibiotic, bacteriophage, etc.) and/or plant defense activator.Type: ApplicationFiled: November 25, 2013Publication date: March 20, 2014Applicant: North Carolina State UniversityInventors: Christian Melander, John Cavanagh, David Ritchie, Robert W. Huigens, III, T. Eric Ballard, Justin J. Richards, Thomas W. Lindsey, Jonathan S. Lindsey
-
Patent number: 8673348Abstract: A system for treating or providing prophylaxus against a pulmonary infection is disclosed comprising: a) a pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition, and b) an inhalation delivery device. A method for providing prophylaxis against a pulmonary infection in a patient and a method of reducing the loss of antiinfective encapsulated in a lipid-based composition upon nebulization comprising administering an aerosolized pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition is also disclosed.Type: GrantFiled: November 13, 2012Date of Patent: March 18, 2014Assignee: Insmed IncorporatedInventor: Jeff Weers
-
Patent number: 8673349Abstract: A system for treating or providing prophylaxus against a pulmonary infection is disclosed comprising: a) a pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition, and b) an inhalation delivery device. A method for providing prophylaxis against a pulmonary infection in a patient and a method of reducing the loss of antiinfective encapsulated in a lipid-based composition upon nebulization comprising administering an aerosolized pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition is also disclosed.Type: GrantFiled: November 13, 2012Date of Patent: March 18, 2014Assignee: Insmed IncorporatedInventor: Jeff Weers
-
Publication number: 20140072620Abstract: A system for treating or providing prophylaxus against a pulmonary infection is disclosed comprising: a) a pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition, and b) an inhalation delivery device. A method for providing prophylaxis against a pulmonary infection in a patient and a method of reducing the loss of antiinfective encapsulated in a lipid-based composition upon nebulization comprising administering an aerosolized pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition is also disclosed.Type: ApplicationFiled: November 15, 2013Publication date: March 13, 2014Applicant: Insmed IncorporatedInventor: Jeff Weers
-
Publication number: 20140073595Abstract: The present invention relates to an aromatic substituted pentadienoic acid amides and there use in combination of specific amounts of aromatic amides i.e. 4-alkyl-5-(substituted phenyl)-2(E),4(E)-pentadienoic acid amides, its geometrical isomers or their dihydro or tetrahydro derivatives and an anti-infective drug useful in potentiating the bioefficacy of antiinfective drug. The combination of the present invention is useful in the treatment of certain infections and disease at lower concentration of anti-infectives necessary to inhibit the growth of microbial strains and may also find applications in reducing the resistance in microorganisms.Type: ApplicationFiled: October 11, 2013Publication date: March 13, 2014Applicant: Council Of Scientific and Industrial ResearchInventors: Surrinder KOUL, Jawahir Lal KOUL, Subhash Chandra TANEJA, Pankaj GUPTA, Inshad Ali KHAN, Zahid Mehmood MIRZA, Ashwani KUMAR, Rakesh Kamal JOHRI, Monika PANDITA, Anita KHOSA, Ashok Kumar TIKOO, Subhash Chander Sharma, Vijeshwar VERMA, Ghulam Nabi QAZI
-
Patent number: 8658606Abstract: Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Q3, R1, R2 or R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.Type: GrantFiled: November 14, 2011Date of Patent: February 25, 2014Assignee: Achaogen, Inc.Inventors: Adam Aaron Goldblum, Paola Dozzo, James Bradley Aggen, Martin Sheringham Linsell
-
Patent number: 8653042Abstract: Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Q3, R1, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.Type: GrantFiled: November 14, 2011Date of Patent: February 18, 2014Assignee: Achaogen, Inc.Inventors: Paola Dozzo, Adam Aaron Goldblum, James Bradley Aggen, Martin Sheringham Linsell
-
Patent number: 8653041Abstract: Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein Q1 and Q2 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.Type: GrantFiled: October 15, 2012Date of Patent: February 18, 2014Assignee: Achaogen, Inc.Inventors: Adam Aaron Goldblum, Paola Dozzo, Timothy Robert Kane, James Bradley Aggen, Martin Sheringham Linsell, Darin James Hildebrandt, Micah James Gliedt
-
Publication number: 20140038915Abstract: This invention relates to methods for treating bacterial infection, which methods find utility in the treatment of, for example, infected ulcers, optionally infected diabetic ulcers. In particular, this invention relates to treating bacterial infection, for example, infected diabetic ulcers by topical administration of at least one aminoglycoside antibiotic at the site of infection, in combination with at least one antibacterial agent, which antibacterial agent is administered remote from the site of infection, preferably administered systemically. In a particular embodiment, the present invention relates to a composition for use in treating bacterial infection, the composition comprising gentamicin sulphate (a water-soluble broad-spectrum aminoglycoside antibiotic) uniformly dispersed in a type-I collagen matrix; incombination with at least one systemically-administered antibacterial agent.Type: ApplicationFiled: April 2, 2012Publication date: February 6, 2014Applicant: INNOCOLL TECHNOLOGIES LIMITEDInventor: David Prior
-
Publication number: 20140037735Abstract: A method and a composition for treatment of pulmonary bacterial infections caused by gram-negative bacteria suitable for treatment of infection caused by Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, Serratia marcescens as well as those caused by Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans, and multidrug resistant Pseudomonas aeruginosa, using a concentrated formulation of aztreonam, or a pharmaceutically acceptable salt thereof, delivered as an aerosol or dry powder formulation.Type: ApplicationFiled: October 4, 2013Publication date: February 6, 2014Applicant: GILEAD SCIENCES, INC.Inventor: Alan Bruce Montgomery
-
Publication number: 20140038914Abstract: This invention relates to a compound of Formula 1A: or a pharmaceutically acceptable salt thereof; wherein R1 to R4, R7, R9 to R12 and Y are as defined herein. The invention further relates to pharmaceutical composition comprising said compound or a pharmaceutically acceptable salt thereof; and method of using same for reducing or reversing bacterial resistance to at least one aminoglycoside antibiotic.Type: ApplicationFiled: January 17, 2012Publication date: February 6, 2014Applicant: THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITYInventors: Karine Auclair, Kenward Vong
-
Patent number: 8642075Abstract: A system for treating or providing prophylaxis against a pulmonary infection is disclosed comprising: a) a pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition, and b) an inhalation delivery device. A method for providing prophylaxis against a pulmonary infection in a patient and a method of reducing the loss of antiinfective encapsulated in a lipid-based composition upon nebulization comprising administering an aerosolized pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition is also disclosed.Type: GrantFiled: November 1, 2012Date of Patent: February 4, 2014Assignee: Insmed IncorporatedInventor: Jeff Weers
-
Patent number: 8632804Abstract: A system for treating or providing prophylaxus against a pulmonary infection is disclosed comprising: a) a pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition, and b) an inhalation delivery device. A method for providing prophylaxis against a pulmonary infection in a patient and a method of reducing the loss of antiinfective encapsulated in a lipid-based composition upon nebulization comprising administering an aerosolized pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition is also disclosed.Type: GrantFiled: June 19, 2012Date of Patent: January 21, 2014Assignee: Insmed IncorporatedInventor: Jeff Weers
-
Publication number: 20140011762Abstract: Provided herein are methods and computer-implemented systems for using computer simulations to predict likelihood of a cell population associated with a pathophysiological condition acquiring resistance to a therapeutic agent, to screen for therapeutic agents effective to suppress acquisition of resistance within a cell population and to treat the pathophysiological conditions associated therewith. The computer simulation comprises at least an input/out system and a mathematical model, including operably linked equations, parameter values and constant values, of growth response over a period of time of a cell population in contact with an therapeutic agent. Also provide is a method for determining a best-fit mathematical model of adaptation of a microbial population to a therapeutic agent over time and using the model to simulate microbial population behavior to a therapeutic agent.Type: ApplicationFiled: May 22, 2013Publication date: January 9, 2014Inventors: Vincent H. Tam, Michael Nikolaou
-
Publication number: 20140004173Abstract: Multivesicular liposomes are prepared at commercial scales by combining a first w/o emulsion with a second aqueous solution to form a w/o/w emulsion using a static mixer. Solvent is removed from the resulting emulsion to form multivesicular liposome-containing compositions. Further optional process steps include primary filtration and secondary cross-flow filtration. The products produced according to the processes of the invention can be produced through a series of aseptic steps.Type: ApplicationFiled: March 8, 2013Publication date: January 2, 2014Applicant: Pacira Pharmaceuticals, Inc.Inventor: Pacira Pharmaceuticals, Inc.
-
Publication number: 20140005135Abstract: Disclosed is a stable liquid formulation for parenteral injection comprising a biocompatible non-aqueous solvent and a small molecule drug, or a salt thereof, solubilized within the non-aqueous solvent, wherein the liquid formulation comprises less than 10% by weight residual water, and wherein the volume of the liquid formulation to be parenterally injected is from 0.1 ?l to 3 ml.Type: ApplicationFiled: March 14, 2013Publication date: January 2, 2014Applicant: XERIS PHARMACEUTICALS, INC.Inventors: Steven J. Prestrelski, Nancy Scott
-
Publication number: 20130338059Abstract: This disclosure relates to methods for differentiating between mammals having active and latent Tuberculosis disease, by determining the percentage of polyfunctional CD4+ T-cells expressing TNF-alpha, IFN-gamma, and IL-2, or by determining expression of IL-17.Type: ApplicationFiled: December 22, 2011Publication date: December 19, 2013Applicant: Centre Hospitalier Universitaire VaudoisInventors: Giuseppe Pantaleo, Alexandre Harari, Matthieu Perreau
-
Publication number: 20130323310Abstract: Swellable particles for delivering a working agent to the pulmonary system comprise a plurality of biodegradable particles each formed from a polymer network, each of the plurality of biodegradable particles having a mass mean aerodynamic diameter not exceeding 5 ?m, the particles being swellable by hydration to a size that is greater than 6 ?m volume mean diameter, and a working agent entrapped in the polymer network of each of the plurality of biodegradable particles.Type: ApplicationFiled: April 19, 2013Publication date: December 5, 2013Applicant: STC.UNMInventors: Hugh D. Smyth, Martin J. Donovan
-
Patent number: 8586552Abstract: Aminoglycoside antibiotics of the formula are disclosed. The compounds are useful for treating bacterial infections, particularly infections resistant to known antibiotics.Type: GrantFiled: January 31, 2013Date of Patent: November 19, 2013Assignee: SelectX Pharmaceuticals, Inc.Inventors: Michael G. Chaparian, Michael Brady, Scott Moe, Babu Rao Renikuntla, Srinivas Gadthula, Srinivasarao Meneni, Venkata Sai Prakash Chaturvedula
-
Publication number: 20130303475Abstract: This invention provides a pharmaceutical solution formulation comprising tobramycin, water, sodium chloride and sodium citrate, wherein the formulation has a pH of 4.5-7.0 and an osmolality of 135-200 mOsmol/Kg.Type: ApplicationFiled: March 19, 2013Publication date: November 14, 2013Inventors: Kevin Hawkins, David Higham
-
Publication number: 20130303476Abstract: The present invention is antibiotic compositions, ventilator-based systems and methods relating to ventilator-associated pneumonia (VAP) and ventilator-associated tracheal (VAT) bronchitis. Antibiotic combinations of fosfomycin and an aminoglycoside, preferably amikacin, are administered via an inline nebulizer within the airway of the ventilator. Humidified conditions create an improved aerosol mist to treat VAP and VAT.Type: ApplicationFiled: July 12, 2013Publication date: November 14, 2013Inventor: Alan Bruce Montgomery
-
Publication number: 20130303473Abstract: The invention provides pharmaceutical compositions based on liquid vehicles whose density is substantially higher than that of aqueous physiological fluids. The compositions are useful as medicines in ophthalmology, in particular for the treatment of conditions affecting the posterior segment of an eye. They may be administered topically into the eye or in a minimally invasive manner by periocular injection. Preferred liquid carriers are selected from semifluorinated alkanes.Type: ApplicationFiled: November 10, 2011Publication date: November 14, 2013Applicant: NOVALIQ GmbHInventor: Clive G. Wilson
-
Publication number: 20130302423Abstract: The present invention is antibiotic compositions, ventilator-based systems and methods relating to ventilator-associated pneumonia (VAP) and ventilator-associated tracheal (VAT) bronchitis. Antibiotic combinations of fosfomycin and an aminoglycoside, preferably amikacin, are administered via an inline nebulizer within the airway of the ventilator. Humidified conditions create an improved aerosol mist to treat VAP and VAT.Type: ApplicationFiled: July 12, 2013Publication date: November 14, 2013Inventor: Alan Bruce Montgomery
-
Publication number: 20130287866Abstract: Use of nitric oxide amino acid esters for improving vascular circulation, and prophylaxis or treatment of a condition associated with impaired blood circulation, such as peripheral vascular disease. The nitric oxide amino acid esters may be co-administered with an antimicrobial in topical or transdermal compositions for improving vascular circulation, and prophylaxis or treatment of a condition associated with impaired blood circulation.Type: ApplicationFiled: October 26, 2011Publication date: October 31, 2013Applicant: ORAL DELIVERY TECHNOLOGY LTD.Inventor: Michael Farber
-
Publication number: 20130288951Abstract: Infection-inhibiting compositions suitable for coating surfaces of implantable medical implants, including compositions and devices for coating medical devices in the operating room prior to implantation in a patient. Methods for inhibiting infection at the site of implantation of an orthopedic device in a human or animal subject, comprise rubbing a surface of the device, prior to implantation, with an infection-inhibiting composition having a waxy matrix comprising an infection-inhibiting material selected from the group consisting of a lipid, an antimicrobial agent, and mixtures thereof, wherein a thin layer of the infection-inhibiting material is deposited on the surface of the device. Medical implants which may be treated in the methods of this technology include orthopedic implants. Lipids include long-chain diacylglycerides or triacylglycerides, which may be saturated or unsaturated, such as lecithin or a purified form of phosphatidylcholine.Type: ApplicationFiled: April 26, 2013Publication date: October 31, 2013Applicant: BIOMET MANUFACTURING CORP.Inventors: Karen S. TROXEL, Michael PONTICIELLO, Troy W. HERSHBERGER
-
Publication number: 20130287692Abstract: Disclosed are rifamycin derivatives having antibacterial activities, wherein the compounds have the following general formula: wherein: R is hydrogen or acetyl; R1 and R2 are independently selected from the group consisting of hydrogen, (C1-4) alkyl, benzyloxy, mono- and di-(C1-3) alkylamino-(C1-4)alkyl, (C1-3)alkoxy, (C1-4) alkyl, hydroxy-methyl, hydroxy-(C2-4)-alkyl, and nitro or R1 and R2 taken together with two consecutive carbon atoms of the pyridine nucleus form a benzene ring optionally substituted by one or two methyl or ethyl groups and R3 is hydroxyalkyl (C1-4). In addition, processes to obtain these compounds are described.Type: ApplicationFiled: November 26, 2012Publication date: October 31, 2013Inventor: ALFA WASSERMANN, S.P.A.
-
Publication number: 20130272997Abstract: A biocompatible, polymeric composition is disclosed. The composition comprises a base polymer comprising (i) a prepolymer comprising para-dioxanone (PDO) and trimethylene carbonate (TMC); and (ii) an end-graft polymer chain comprising a polylactone. Also disclosed are a method for treating bleeding from bone or bony structures using the composition, a method for filling a void or correct a defect in a bone using the composition, and a method for producing the biocompatible, polymeric composition of the present application.Type: ApplicationFiled: April 12, 2012Publication date: October 17, 2013Applicant: Poly-Med, Inc.Inventors: Kenneth David Gray, JR., Michael Scott Taylor
-
Publication number: 20130263852Abstract: The present invention is antibiotic compositions, ventilator based systems and methods relating to ventilator-associated pneumonia (VAP) and ventilator-associated tracheal (VAT) bronchitis. Antibiotic combinations of fosfomycin and an aminoglycoside, preferably amikacin, are administered via an in-line nebulizer within the airway of the ventilator. Humidified conditions create an improved aerosol mist to treat VAP and VAT.Type: ApplicationFiled: March 15, 2013Publication date: October 10, 2013Inventor: Alan Bruce Montgomery
-
Publication number: 20130251790Abstract: The present invention provides a pharmaceutical composition comprising a low dose of zanamivir and a process for preparing the pharmaceutical composition comprising a low dose of zanamivir. The pharmaceutical composition comprising a low dose zanamivir may be used in the treatment and/or prophylaxis of influenza. The present invention also provides a method of treatment and/or prophylaxis of influenza which comprises administering a dry powder inhaler composition comprising a low dose zanamivir. The pharmaceutical composition of the present invention comprises zanamivir and one or more pharmaceutically acceptable excipients, wherein the total daily dose of the zanamivir is less than 10 mg, preferably for administration at least once a day, and preferably wherein the composition delivers from 3 mg to 8 mg of zanamivir per administered dose.Type: ApplicationFiled: September 26, 2011Publication date: September 26, 2013Applicant: CIPLA LIMITEDInventors: Geena Malhotra, Shrinivas Madhukar Purandare